Search

Your search keyword '"Catalá, Eva"' showing total 17 results
Start Over Author "Catalá, Eva"
17 results on '"Catalá, Eva"'

3. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies

Author

Jiménez, Moraima, Roldán, Elisa, Fernández-Naval, Candela, Villacampa, Guillermo, Martinez-Gallo, Mónica, Medina-Gil, Daniel, Peralta-Garzón, Soraya, Pujadas, Gemma, Hernández, Cristina, Pagès, Carlota, Gironella, Mercedes, Fox, Laura, Orti, Guillermo, Barba, Pere, Pumarola, Tomás, Cabirta, Alba, Catalá, Eva, Valentín, Mercedes, Marín-Niebla, Ana, Orfao, Alberto, González, Marcos, Campins, Magda, Ruiz-Camps, Isabel, Valcárcel, David, Bosch, Francesc, Hernández, Manuel, Crespo, Marta, Esperalba, Juliana, and Abrisqueta, Pau

Published
2022
Full Text
View/download PDF

5. The Mid-Infrared Instrument for JWST, II: Design and Build

Author

Wright, G. S., Wright, David, Goodson, G. B., Rieke, G. H., Aitink-Kroes, Gabby, Amiaux, J., Aricha-Yanguas, Ana, Azzolini, Ruyman, Banks, Kimberly, Barrado-Navascues, D., Belenguer-Davila, T., Bloemmart, J. A. D. L., Bouchet, Patrice, Brandl, B. R., Colina, L., Detre, Ors, Diaz-Catala, Eva, Eccleston, Paul, Friedman, Scott D., Garcia-Marin, Macarena, Guedel, Manuel, Glasse, Alistair, Glauser, Adrian M., Greene, T. P., Groezinger, Uli, Grundy, Tim, Hastings, Peter, Henning, Th., Hofferbert, Ralph, Hunter, Faye, Jessen, N. C., Justtanont, K., Karnik, Avinash R., Khorrami, Mori A., Krause, Oliver, Labiano, Alvaro, Lagage, P. -O., Langer, Ulrich, Lemke, Dietrich, Lim, Tanya, Lorenzo-Alvarez, Jose, Mazy, Emmanuel, McGowan, Norman, Meixner, M. E., Morris, Nigel, Morrison, Jane E., Mueller, Friedrich, Norgaard-Nielson, H. -U., Olofsson, Goeran, O'Sullivan, Brian, Pel, J. -W., Penanen, Konstantin, Petach, M. B., Pye, J. P., Ray, T. P., Renotte, Etienne, Renouf, Ian, Ressler, M. E., Samara-Ratna, Piyal, Scheithauer, Silvia, Schneider, Analyn, Shaughnessy, Bryan, Stevenson, Tim, Sukhatme, Kalyani, Swinyard, Bruce, Sykes, Jon, Thatcher, John, Tikkanen, Tuomo, van Dishoeck, E. F., Waelkens, C., Walker, Helen, Wells, Martyn, and Zhender, Alex

Subjects
Astrophysics - Instrumentation and Methods for Astrophysics
Abstract

The Mid-InfraRed Instrument (MIRI) on the James Webb Space Telescope (JWST) provides measurements over the wavelength range 5 to 28.5 microns. MIRI has, within a single 'package', four key scientific functions: photometric imaging, coronagraphy, single-source low-spectral resolving power (R ~ 100) spectroscopy, and medium-resolving power (R ~ 1500 to 3500) integral field spectroscopy. An associated cooler system maintains MIRI at its operating temperature of < 6.7 K. This paper describes the driving principles behind the design of MIRI, the primary design parameters, and their realization in terms of the 'as-built' instrument. It also describes the test program that led to delivery of the tested and calibrated Flight Model to NASA in 2012, and the confirmation after delivery of the key interface requirements.

Published
2015
Full Text
View/download PDF

7. P1401: IDENTIFICATION OF BIOMARKERS AND RISK FACTORS FOR IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME (ICANS) IN CD19-DIRECTED CAR T-CELL THERAPY: A RETROSPECTIVE MACHINE LEARNING-BASED ANALYSIS.

Author

Gómez-Llobell, Marina, primary, Martínez García, María, additional, Serra Smith, Carlos, additional, Gómez Costas, Daniel, additional, Oarbeascoa Royuela, Gillen, additional, Carbonell, Diego, additional, Anguita Velasco, Javier, additional, Corral, Ana María Pérez, additional, Pion, Marjorie, additional, Astrid Pérez-Fernández, Veronica, additional, Fernández García, Isabel, additional, Bastos Oreiro, Mariana, additional, Fernández-Caldas González, Paula, additional, Gómez-Centurión, Ignacio, additional, Alarcón, Ana, additional, Catalá, Eva, additional, Conde, Diego, additional, Gayoso, Jorge, additional, Olmos, Pablo, additional, Martínez Laperche, Carolina, additional, García-Domínguez, Jose, additional, Fernández, Yolanda, additional, Bailen, Rebeca, additional, and Kwon, MI, additional

Published
2023
Full Text
View/download PDF

9. Variant t(11;22)(q13;q11.2) with IGL involvement in mantle cell lymphoma

Author

Cabirta, Alba, primary, Hidalgo-Gómez, Gloria, additional, Marín-Niebla, Ana, additional, Gallur, Laura, additional, Saumell, Silvia, additional, Castellví, Josep, additional, Catalá, Eva, additional, Blanco, Adoración, additional, López-Andreoni, Laura, additional, Montoro, María Julia, additional, Navarrete, Mayda, additional, Palacio-García, Carlos, additional, Tazón-Vega, Bárbara, additional, Bobillo, Sabela, additional, Bosch, Francesc, additional, and Ortega, Margarita, additional

Published
2022
Full Text
View/download PDF

12. Outcomes of CAR-T Cell Therapy for Large B Cell Lymphoma in Patients of 70 Years and Older: Multicentric Experience on Behalf of Geth-TC/Geltamo

Author

Bailen, Rebeca, Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Lopez Corral, Lucia, Hernani, Rafael, Ortiz-Maldonado, Valentin, Guerreiro, Manuel, Caballero Gonzalez, Ana Carolina, Guerra, Luisa, Sanchez Pina, Jose Maria, Mussetti, Alberto, Sancho, Juan-Manuel, Bastos-Oreiro, Mariana, Catalá, Eva, Delgado Serrano, Javier, Luzardo Henriquez, Hugo Daniel, Caballer, Jaime Sanz, Calbacho, Maria, Carpio, Cecilia, Ribera, Josep-Maria, Torrent, Anna, Sureda Balari, Anna Maria, Briones, Javier, Hernandez Boluda, Juan Carlos, Martinez-Cibrian, Nuria, Martin Garcia-Sancho, Alejandro, and Barba, Pere

Published
2023
Full Text
View/download PDF

13. Selection process and causes of non-eligibility for CD19 CAR-T cell therapy in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma in a European center

Author

Carpio, Cecilia, primary, Iacoboni, Gloria, additional, Villacampa, Guillermo, additional, Catalá, Eva, additional, Bobillo, Sabela, additional, Pérez, Ana, additional, Jiménez, Moraima, additional, Segura, Laura, additional, Olivé, Mireia, additional, Farriols, Anna, additional, Abrisqueta, Pau, additional, Valcárcel, David, additional, Carreras, María Josep, additional, Bosch, Francesc, additional, and Barba, Pere, additional

Published
2021
Full Text
View/download PDF

14. Axicabtagene Ciloleucel Compared to Tisagenlecleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma in the Real World Setting in Spain

Author

Kwon, Mi, Iacoboni, Gloria, Reguera, Juan Luis, Lopez Corral, Lucia, Hernani, Rafael, Guerreiro, Manuel, Caballero, Ana Carolina, Ortiz-Maldonado, Valentín, Sanchez, Jose M., Paviglianiti, Annalisa, Sancho, Juan-Manuel, Bastos-Oreiro, Mariana, Oarbeascoa, Gillen, Martin Rojas, Reyes Maria, Catala, Eva, Delgado Serrano, Javier, Mussetti, Alberto, Sanz, Jaime, Calbacho, Maria, Bailen, Rebeca, Briones, Javier, Hernandez Boluda, Juan Carlos, Martin Garcia-Sancho, Alejandro, Diez-Martin, Jose L., and Barba, Pere

Published
2021
Full Text
View/download PDF

15. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Hematologic Patients: Experience at the Hospital Attending More Patients in Spain

Author

Cabirta, Alba, Izuzquiza, Macarena, Ruiz-Camps, Isabel, Valcarcel, David, Catala, Eva, Jimenez, M Moraima, Perez, Ana, Martin, Lucia, Rodriguez, Yva, Serna, Angel, Ruiz-Pace, Fiorella, Dienstmann, Rodrigo, Bobillo, Sabela, Carpio, Cecilia, Salamero, Olga, Abrisqueta, Pau, and Bosch, Francesc

Published
2020
Full Text
View/download PDF

16. Terapia con linfocitos T con receptor de antígeno quimérico (CAR-T) en pacientes con linfoma de célula B agresivos. Perspectiva actual tras una década de tratamiento

Author

Catalá, Eva, Iacoboni, Gloria, and Barba, Pere

Abstract

La terapia con linfocitos T con receptor de antígeno quimérico (CAR-T) ha revolucionado el manejo de los pacientes con linfoma difuso de células grandes B (LDCGB) refractarios o en recaída tras inmunoquimioterapia. Esta estrategia consiste en modificar genéticamente los linfocitos T de los propios pacientes para favorecer el reconocimiento de los antígenos tumorales seleccionados. Actualmente hay disponibles 2 medicamentos CAR-T anti-CD19 aprobados en España para pacientes con LDCGB tras 2 o más líneas de tratamiento sistémico previo y existen múltiples ensayos clínicos en marcha investigando su uso en líneas de tratamiento más precoces. Tanto los ensayos clínicos pivotales como los datos de práctica asistencial post-comercialización han contribuido a definir el perfil de eficacia y seguridad de cada constructo, identificar los principales factores pronósticos de respuesta y optimizar el manejo de las distintas fases de esta terapia. Todos estos aspectos se repasan en esta revisión.

Published
2021
Full Text
View/download PDF

17. Advantages of high cell concentration prior to cryopreservation of initial leukapheresis in CAR-T cell therapy.

Author

Carbonell D, Monsalvo S, Catalá E, Pérez-Corral A, Villegas C, Falero C, Ruano G, Martinez M, Kwon M, Muñoz-Martínez C, Díez-Martín JL, Gayoso J, and Anguita J

Subjects
Humans, Female, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma therapy, Adult, Middle Aged, Receptors, Chimeric Antigen, Aged, T-Lymphocytes cytology, Leukapheresis methods, Cryopreservation methods, Immunotherapy, Adoptive methods, Immunotherapy, Adoptive economics
Abstract

Background: Chimeric antigen receptor (CAR) T-cell therapy is increasingly used in patients affected by B-cell lymphoma and acute lymphoblastic leukemia. For logistical reasons, initial apheresis products may be cryopreserved for shipment to manufacturing centers. Due to the characteristics of these patients, cells are often collected in large volumes, meaning more bags must be cryopreserved. This requires increased storage, time and monetary costs. In this context, we aimed to evaluate a high cell concentration cryopreservation protocol by centrifugation to standardize the initial CAR-T manufacturing procedure., Materials and Methods: Sixty-eight processes of leukapheresis of 57 patients affected by refractory/relapsed B cell lymphoma and 9 patients affected by acute lymphoblastic leukemia who were eligible for anti-CD19 CAR-T cell treatment performed between June 2019 and October 2022 were analyzed. Whole blood count, percentage and number of T cells were assessed on the apheresis final product. The apheresis product, which was alternatively stored overnight at 4°C, was centrifuged, adjusting the volume to approximately 40 mL. The product was immediately cryopreserved to achieve a final cell concentration of 50-200×10 6 cells/ml for cryopreservation., Results: Leukapheresis volume was reduced by almost fivefold (median: 185 to 40 mL), resulting in a higher product concentration in one bag. In addition, the number of non-target cells (monocytes, platelets and erythrocytes) was also reduced during the development of CAR-T cell therapy, thereby maintaining T lymphocyte levels and providing a purer starting material., Discussion: The advantages of the protocol include reducing economic costs, saving storage space, simplifying the manufacturing process, and facilitating shipping logistics. In conclusion, we present a validated, simple, and cost-effective cell enrichment processing protocol that provides high-quality cryopreserved products as starting material for the CAR-T cell manufacturing process.

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results